Navigation Links
Using Product Marketing to Launch Drugs That Outperform the Competition
Date:1/17/2008

CHAPEL HILL, N.C., Jan. 17 /PRNewswire/ -- With so much riding on new product development and market launch, the pharma industry is continually seeking to improve the expensive and time-consuming process. To launch drugs that outperform the competition, leading firms are focusing more marketing resources on the early stages of development, according to research from benchmarking leader Best Practices, LLC.

For instance, while many companies limit marketing spending in early stages to 10 percent of total pre-launch spending, organizations with consistently high product performance reported early stage spending levels as high as 27 percent, according to the study.

"Early marketing insights pay off at launch," said Cameron Tew, senior manager of research and publishing at Best Practices, LLC. "Companies that have achieved faster and higher sales uptake with new products are committing sufficient marketing resources as early as the pre-clinical phase."

The 169-page report, "Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters," includes 96 best practices drawn from surveys and interviews with 24 executives at more than 15 leading pharmaceutical and biotechnology companies such as Pfizer, Merck, Sanofi-Aventis, GlaxoSmithKline, Eli Lilly, Amgen, Boehringer-Ingelheim and Novartis.

For a complimentary download of a study excerpt, visit http://www3.best-in-class.com/rr900.htm .

Marketing and branding decision-makers can use the report to gather insights on development topics ranging from marketing investment and expense patterns to thought leader development for high-potential products. In addition, the report includes marketing success stories for 16 of the world's top selling drugs.

Some of the study findings include:

-- Companies that consistently launch blockbuster drugs foster a culture

that actively suppor
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Holiday Visits Nudge Many Towards Senior Housing Decision
2. Researchers seek to make cavity-causing bacteria self-destruct
3. Winemaking waste proves effective against disease-causing bacteria in early studies
4. Novare Announces Completion of 100th Single Port Laparoscopic Procedure Using RealHand(R) High Dexterity (HD) Instruments
5. Using Early Stage Commercialization Activities to Build Long-Term Success for the Bottom Line
6. Reserve 2008 Budget for Using Quality to Improve the Customer Experience
7. Older Diabetics Using Avandia Face Increased Death Risk
8. Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward
9. UCSF Medical Center using newest high-tech tool for brain disorders
10. Mini transplant patients outcomes similar using related and unrelated donor cells
11. Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... ... Text results have been impressive so far". , Mr Cauchois attributes the ... Winscribe's French sales partner Dicma and the healthcare technology offered by Winscribe's platform. ...
(Date:8/3/2015)... ... 2015 , ... While the pace of the economic recovery since the 2008 has been subject ... growth trajectory for the last six years. Unemployment has dropped from a 2009 high of ... percent growth rate in 2014, the U.S. stock market is at an all time high, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Zeiter’s Septic ... As a family owned and operated business, Zeiter’s Septic has been serving the ... leader in septic installations because of their continued training and perseverance to provide ...
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
Breaking Medicine News(10 mins):Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 2Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 3Health News:Newport Board group, an Advisory Firm Serving the Middle Market, Cautions Businesses on How to Survive the Coming Recession 4Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... 10 "The Senate compromise version of H.R. 1, ... no relief to the thousands of state and local ... economic downturn - including those who work in laboratories," ... Public Health Laboratories. "Unfortunately, the Senate has decided that ...
... Inc. (NYSE: NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the following preliminary unaudited ... NET SALES, ... FOR THE ... ($In Millions), ...
... Potential sale increases focus on growing core businessesCHICAGO, Feb. ... that it has reached an agreement in principle, subject ... to sell its Medication Services business. Closing of the ... conditions, but no assurances can be given that a ...
... as HPV tweak their DNA to escape detection, study ... of cancer-related viruses may actually change to disguise themselves from ... international team of scientists studied the entire genomes of three ... hepatitis B. Each of these pathogens can progress into cancer ...
... even if you stop taking the drug, study finds , , ... aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to reduce ... cancer. , That,s the conclusion of a new study of ... clear, and arguably proven, that NSAID drugs do interfere with ...
... of the Center for Research on Minority Health ... Member for NPAF and PAF, Honored for His ... Feb. 10 The National Patient Advocate Foundation ... that a member of the Foundations, Executive Boards, ...
Cached Medicine News:Health News:Laid Off Public Health Workers Excluded From Senate Stimulus, Governmental Health Laboratories Slammed by Recession 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for January 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for January 2009 3Health News:Allscripts Announces Agreement in Principle to Sell Its Medication Services Business 2Health News:Allscripts Announces Agreement in Principle to Sell Its Medication Services Business 3Health News:Genes Help Cancer-Linked Viruses Elude Immune System 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 2Health News:Long-Term Aspirin Use Seems to Protect Against Colorectal Lesions 3Health News:Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award 2Health News:Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award 3
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), maker of ... Andrew J. Whelan , President will be interviewed ... Business" at 9am EDT on Wednesday, August 5 th ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. ... the company,s flagship product, ActiPatch Therapy, is achieving in ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, ... of its second clinical development program with a ... CL-H1T.  CL-H1T contains fast-dissolving promethazine ... developed as a treatment for migraine headache pain ... "Many patients with migraine headaches also suffer ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... Md., Nov. 28, 2011 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, announced today that ... present at the Piper Jaffray 23rd Annual Healthcare Conference ... Richman will also be available to participate in one-on-one ...
... Conn., Nov. 28, 2011 Gaylord Sleep Medicine now ... their Glastonbury, Guilford, North Haven and Trumbull locations. ... new Sleep Apnea Management program has expanded to offer ... patient needs. Originally designed to improve PAP compliance, the ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2Gaylord Sleep Medicine Expands Sleep Apnea Management Program 2
Replacement bulb for Vibratome light system....
The V-Block adapter is designed to allow round posts to be placed in the Vibratome vice....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
... includes everything from the care package ... Spare Fluorescent Bulb, additional Vibratome Feather ... and a Specimen Tray. ... 1/2" speciment mounts, replacement rotating mounts, ...
Medicine Products: